Rhythm Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Rhythm Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | ||||||||||||||||||||||||||||||||
| assets | ||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||
| cash and cash equivalents | 135,586,000 | 106,095,000 | 89,137,000 | 47,521,000 | 161,669,000 | 53,428,000 | 60,081,000 | 64,593,000 | 115,684,000 | 109,661,000 | 127,677,000 | 185,087,000 | 113,207,000 | 78,537,000 | 59,248,000 | 92,372,000 | 69,339,000 | 87,271,000 | 100,854,000 | 67,670,000 | 59,091,000 | 55,776,000 | 62,294,000 | 71,680,000 | 63,118,000 | 42,020,000 | 49,542,000 | 58,247,000 | 210,484,000 | 43,167,000 | 34,236,000 | 27,914,000 |
| short-term investments | 155,444,000 | 208,393,000 | 231,428,000 | 250,869,000 | 157,461,000 | 147,771,000 | 215,765,000 | 234,667,000 | 137,918,000 | 184,921,000 | 205,611,000 | 162,708,000 | 122,389,000 | 162,427,000 | 235,607,000 | 235,982,000 | 298,815,000 | 317,479,000 | 71,938,000 | 134,114,000 | 169,535,000 | 201,648,000 | 230,165,000 | 90,755,000 | 132,049,000 | 179,503,000 | 202,519,000 | 214,139,000 | 77,070,000 | 93,286,000 | 113,846,000 | 2,501,000 |
| accounts receivable | 26,122,000 | 17,825,000 | 18,512,000 | 19,306,000 | 17,598,000 | 14,695,000 | 14,867,000 | 14,541,000 | 13,831,000 | 8,117,000 | 6,224,000 | 3,328,000 | 1,707,000 | 862,000 | 1,025,000 | |||||||||||||||||
| inventory | 18,872,000 | 19,316,000 | 18,741,000 | 13,895,000 | 11,994,000 | 8,507,000 | 8,624,000 | 7,762,000 | 6,178,000 | 5,487,000 | 2,917,000 | |||||||||||||||||||||
| prepaid expenses and other current assets | 24,656,000 | 17,659,000 | 16,382,000 | 8,750,000 | 8,644,000 | 11,352,000 | 8,931,000 | 7,638,000 | 10,267,000 | 9,652,000 | 11,807,000 | 10,751,000 | 12,029,000 | 11,623,000 | 12,507,000 | 7,282,000 | 10,300,000 | 7,384,000 | 8,876,000 | 8,130,000 | 9,193,000 | 10,436,000 | 9,945,000 | 8,442,000 | 8,334,000 | 8,646,000 | 6,628,000 | 4,152,000 | 3,217,000 | 1,961,000 | 2,589,000 | 1,621,000 |
| total current assets | 360,680,000 | 369,288,000 | 374,200,000 | 340,341,000 | 357,366,000 | 235,753,000 | 308,268,000 | 329,201,000 | 283,878,000 | 317,838,000 | 354,236,000 | 361,874,000 | 249,332,000 | 253,449,000 | 308,387,000 | 335,636,000 | 378,454,000 | 412,134,000 | 181,668,000 | 209,914,000 | 237,819,000 | 267,860,000 | 302,404,000 | 170,877,000 | 203,501,000 | 230,169,000 | 258,689,000 | 276,538,000 | 290,771,000 | 138,414,000 | 150,671,000 | 32,036,000 |
| property and equipment | 297,000 | 462,000 | 632,000 | 801,000 | 973,000 | 1,149,000 | 1,341,000 | 1,545,000 | 1,773,000 | 2,001,000 | 2,197,000 | 2,426,000 | 2,559,000 | 2,722,000 | 2,813,000 | 2,956,000 | 3,051,000 | 3,006,000 | 3,195,000 | 3,289,000 | 3,331,000 | 3,504,000 | 3,671,000 | 3,862,000 | 3,901,000 | 2,757,000 | ||||||
| right-of-use asset | 3,262,000 | 3,367,000 | 3,477,000 | 3,588,000 | 3,696,000 | 670,000 | 781,000 | 888,000 | 990,000 | 1,088,000 | 1,182,000 | 1,273,000 | 1,359,000 | 1,442,000 | 1,522,000 | 1,598,000 | 1,671,000 | 1,741,000 | 1,807,000 | 1,871,000 | 1,932,000 | 1,989,000 | 2,045,000 | 2,097,000 | 3,085,000 | 3,174,000 | ||||||
| intangible assets | 5,747,000 | 5,960,000 | 6,174,000 | 6,388,000 | 6,601,000 | 6,815,000 | 7,028,000 | 7,242,000 | 7,456,000 | 7,669,000 | 7,883,000 | 8,097,000 | 8,311,000 | 8,527,000 | 4,658,000 | 4,772,000 | 4,886,000 | 5,000,000 | ||||||||||||||
| restricted cash | 527,000 | 464,000 | 464,000 | 462,000 | 460,000 | 460,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 328,000 | 403,000 | 403,000 | 403,000 | 403,000 | 403,000 | 402,000 | 401,000 | 402,000 | 401,000 | 251,000 | 250,000 | 250,000 | 225,000 | 225,000 |
| other long-term assets | 2,220,000 | 7,144,000 | 7,326,000 | 11,992,000 | 12,750,000 | 13,804,000 | 14,999,000 | 14,995,000 | 15,518,000 | 16,754,000 | 16,655,000 | 15,616,000 | 15,786,000 | 18,356,000 | 11,815,000 | 10,533,000 | ||||||||||||||||
| total assets | 372,733,000 | 386,685,000 | 392,273,000 | 363,572,000 | 381,846,000 | 258,651,000 | 332,745,000 | 354,199,000 | 309,943,000 | 345,678,000 | 382,481,000 | 389,614,000 | 277,675,000 | 284,824,000 | 329,523,000 | 355,823,000 | 388,390,000 | 422,209,000 | 187,073,000 | 215,477,000 | 243,485,000 | 273,756,000 | 308,523,000 | 177,533,000 | 210,888,000 | 236,502,000 | 260,210,000 | 277,728,000 | 291,749,000 | 139,443,000 | 151,736,000 | 34,804,000 |
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||
| accounts payable | 15,982,000 | 11,912,000 | 12,328,000 | 4,887,000 | 4,543,000 | 7,550,000 | 4,885,000 | 3,839,000 | 8,383,000 | 13,347,000 | 4,797,000 | 4,933,000 | 6,012,000 | 12,010,000 | 5,737,000 | 4,614,000 | 5,009,000 | 9,147,000 | 4,900,000 | 3,793,000 | 4,761,000 | 5,932,000 | 10,415,000 | 7,745,000 | 6,565,000 | 3,992,000 | 7,640,000 | 208,000 | 3,312,000 | 2,456,000 | 2,427,000 | 2,271,000 |
| accrued expenses and other current liabilities | 69,185,000 | 59,314,000 | 62,658,000 | 54,797,000 | 48,077,000 | 44,531,000 | 48,262,000 | 44,271,000 | 35,708,000 | 30,549,000 | 32,894,000 | 25,741,000 | 35,605,000 | 25,199,000 | 30,084,000 | 18,265,000 | 11,880,000 | 7,150,000 | 12,559,000 | 11,536,000 | 9,640,000 | 11,277,000 | 13,530,000 | 17,005,000 | 19,146,000 | 8,373,000 | 5,942,000 | 7,595,000 | 3,849,000 | 3,038,000 | 4,210,000 | 3,108,000 |
| other current liability - lg chem | 40,000,000 | 38,783,000 | 37,704,000 | 36,635,000 | ||||||||||||||||||||||||||||
| lease liability | 510,000 | 224,000 | 816,000 | 793,000 | 770,000 | 748,000 | 726,000 | 705,000 | 684,000 | 664,000 | 644,000 | 625,000 | 606,000 | 588,000 | 570,000 | 553,000 | 535,000 | 519,000 | 503,000 | 487,000 | 472,000 | 457,000 | 379,000 | 202,000 | ||||||||
| deferred revenue | 1,286,000 | 1,286,000 | 1,286,000 | 1,286,000 | 1,286,000 | 1,286,000 | 1,286,000 | 1,428,000 | 1,434,000 | 1,760,000 | 2,309,000 | |||||||||||||||||||||
| deferred royalty obligation, current | 3,778,000 | 1,590,000 | 1,541,000 | |||||||||||||||||||||||||||||
| total current liabilities | 129,455,000 | 111,823,000 | 115,517,000 | 97,605,000 | 54,722,000 | 54,160,000 | 55,203,000 | 50,144,000 | 46,103,000 | 46,029,000 | 39,809,000 | 33,098,000 | 44,570,000 | 47,274,000 | 43,427,000 | 23,467,000 | 17,459,000 | 16,850,000 | 17,994,000 | 15,848,000 | 14,904,000 | 17,696,000 | 24,417,000 | 25,207,000 | 26,090,000 | 12,567,000 | 13,582,000 | 7,803,000 | 7,247,000 | 5,579,000 | 6,720,000 | 5,460,000 |
| long-term liabilities: | ||||||||||||||||||||||||||||||||
| deferred royalty obligation | 106,014,000 | 107,934,000 | 108,269,000 | 109,241,000 | 108,372,000 | 107,368,000 | 106,143,000 | 104,699,000 | 79,347,000 | 77,520,000 | 75,810,000 | 72,961,000 | 34,273,000 | |||||||||||||||||||
| lease liability, non-current | 3,681,000 | 3,839,000 | 3,938,000 | 4,030,000 | 3,301,000 | 284,000 | 490,000 | |||||||||||||||||||||||||
| total liabilities | 239,150,000 | 223,596,000 | 227,724,000 | 210,876,000 | 202,351,000 | 197,070,000 | 162,986,000 | 156,725,000 | 127,658,000 | 125,915,000 | 118,219,000 | 108,419,000 | 82,047,000 | 49,055,000 | 45,372,000 | 33,560,000 | 36,701,000 | 41,262,000 | 20,545,000 | 18,540,000 | 17,732,000 | 20,655,000 | 27,503,000 | 28,418,000 | 29,421,000 | 16,013,000 | 13,954,000 | 8,091,000 | 7,432,000 | 5,785,000 | 6,948,000 | 5,710,000 |
| commitments and contingencies | ||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value: 150,000 shares authorized; 150,000 and 150,000 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively. liquidation preference of 150,000 as of june 30, 2025. | 145,491,000 | |||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||
| common stock | 64,000 | 62,000 | 61,000 | 61,000 | 60,000 | 60,000 | 59,000 | 59,000 | 57,000 | 56,000 | 56,000 | 56,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 44,000 | 44,000 | 44,000 | 44,000 | 44,000 | 35,000 | 34,000 | 34,000 | 34,000 | 34,000 | 34,000 | 27,000 | 27,000 | 2,000 |
| additional paid-in capital | 1,241,744,000 | 1,223,772,000 | 1,177,045,000 | 1,123,768,000 | 1,108,269,000 | 1,097,810,000 | 1,064,302,000 | 1,050,631,000 | 991,182,000 | 981,950,000 | 974,356,000 | 949,043,000 | 823,188,000 | 818,051,000 | 813,041,000 | 808,265,000 | 802,584,000 | 796,532,000 | 625,762,000 | 621,085,000 | 615,691,000 | 612,552,000 | 606,307,000 | 441,455,000 | 437,805,000 | 434,031,000 | 430,824,000 | 428,698,000 | 425,406,000 | 260,342,000 | 255,013,000 | 47,784,000 |
| accumulated other comprehensive | -2,248,000 | -51,000 | ||||||||||||||||||||||||||||||
| accumulated deficit | -1,251,468,000 | -1,204,836,000 | -1,155,338,000 | -1,112,010,000 | -1,068,369,000 | -1,036,108,000 | -894,736,000 | -853,103,000 | -808,940,000 | -762,237,000 | -710,058,000 | -667,565,000 | -626,704,000 | -581,703,000 | -528,939,000 | -486,073,000 | -450,966,000 | -415,577,000 | -459,327,000 | -424,430,000 | -390,612,000 | -359,495,000 | -325,331,000 | -292,375,000 | -256,372,000 | -213,576,000 | -184,602,000 | -159,095,000 | -141,123,000 | -126,711,000 | -110,252,000 | -99,721,000 |
| total stockholders’ equity | -11,908,000 | 18,947,000 | 21,729,000 | 11,215,000 | 39,343,000 | 61,581,000 | 169,759,000 | 197,474,000 | 182,285,000 | 219,763,000 | 264,262,000 | 281,195,000 | 195,628,000 | 235,769,000 | 284,151,000 | 322,263,000 | 351,689,000 | 380,947,000 | 166,528,000 | 196,937,000 | 225,753,000 | 253,101,000 | 281,020,000 | 149,115,000 | 181,467,000 | 220,489,000 | 246,256,000 | 269,637,000 | 284,317,000 | 133,658,000 | 144,788,000 | -51,856,000 |
| total liabilities, convertible preferred stock and stockholders’ equity | 372,733,000 | 386,685,000 | 392,273,000 | 363,572,000 | 381,846,000 | 260,210,000 | 277,728,000 | 291,749,000 | 139,443,000 | 151,736,000 | 34,804,000 | |||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value: 150,000 shares authorized; 150,000 and 150,000 shares issued and outstanding at march 31, 2025 and december 31, 2024, respectively. liquidation preference of 150,000 as of march 31, 2025. | 144,142,000 | |||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||
| derivative liability | 360,000 | 660,000 | 1,150,000 | 1,190,000 | 1,320,000 | 1,290,000 | 1,340,000 | 920,000 | 1,590,000 | |||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value: 150,000 shares authorized; 150,000 and 0 shares issued and outstanding at december 31, 2024 and december 31, 2023, respectively. liquidation preference of 150,000 as of december 31, 2024. | 142,820,000 | |||||||||||||||||||||||||||||||
| accumulated other comprehensive income | -39,000 | -604,000 | -617,000 | -181,000 | 134,000 | -1,000 | 21,000 | 21,000 | -58,000 | 49,000 | 238,000 | 630,000 | ||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value: 150,000 shares authorized; 150,000 and 0 shares issued and outstanding at september 30, 2024 and december 31, 2023, respectively. liquidation preference of 150,000 as of september 30, 2024. | 141,481,000 | |||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||
| other long-term liabilities | 35,596,000 | 34,598,000 | ||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value: 150,000 shares authorized; 150,000 and 0 shares issued and outstanding at june 30, 2024 and december 31, 2023, respectively. liquidation preference of 150,000 as of june 30, 2024. | 140,152,000 | |||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ equity | 258,651,000 | 332,745,000 | 354,199,000 | 309,943,000 | 345,678,000 | 382,481,000 | 389,614,000 | 277,675,000 | 284,824,000 | 329,523,000 | 355,823,000 | 388,390,000 | 422,209,000 | 187,073,000 | 215,477,000 | 243,485,000 | 273,756,000 | 308,523,000 | 177,533,000 | 210,888,000 | 236,502,000 | |||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -113,000 | -14,000 | -6,000 | -92,000 | -339,000 | -906,000 | -629,000 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||
| contract liability | 9,440,000 | 7,000,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||
| deferred tax liability | 7,989,000 | 16,984,000 | 22,006,000 | |||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | ||||||||||||||||||||||||||||||||
| deferred rent | 86,000 | 85,000 | 83,000 | 81,000 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2019 and 2018 | ||||||||||||||||||||||||||||||||
| deferred issuance costs | 295,000 | 1,698,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2019 and december 31, 2018, respectively | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2019 and december 31, 2018, respectively | ||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively | ||||||||||||||||||||||||||||||||
| property, plant and equipment | 1,120,000 | 939,000 | 728,000 | 779,000 | 840,000 | 845,000 | ||||||||||||||||||||||||||
| preferred stock: | ||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||
| due to related party | ||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at december 31, 2017 and 40,000,000 shares issued and outstanding at december 31, 2016; | ||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 1.00 par value: 80,950,000 shares authorized; 80,949,999 shares issued and outstanding at september 30, 2017 and 40,000,000 shares issued and outstanding at december 31, 2016; | 80,950,000 | |||||||||||||||||||||||||||||||
| series a-1 convertible junior preferred stock, 0.001 par value, 78,666,209 shares authorized; 78,666,209 and no shares issued and outstanding at september 30, 2017 and december 31, 2016, respectively | 79,000 |
We provide you with 20 years of balance sheets for Rhythm Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Rhythm Pharmaceuticals. Explore the full financial landscape of Rhythm Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Rhythm Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.